PT - JOURNAL ARTICLE AU - Riffat Mehboob AU - Fridoon Jawad Ahmad AU - Ahad Qayyum AU - Muhammad Asim Rana AU - Syed Amir Gilani AU - Muhammad Akram Tariq AU - Gibran Ali AU - Shehla Javed Akram AU - Javed Akram TI - Aprepitant as a combinant with Dexamethasone reduces the inflammation via Neurokinin 1 Receptor Antagonism in severe to critical Covid-19 patients and potentiates respiratory recovery: A novel therapeutic approach AID - 10.1101/2020.08.01.20166678 DP - 2020 Jan 01 TA - medRxiv PG - 2020.08.01.20166678 4099 - http://medrxiv.org/content/early/2020/12/17/2020.08.01.20166678.short 4100 - http://medrxiv.org/content/early/2020/12/17/2020.08.01.20166678.full AB - Corona virus infection is a respiratory infection, compromising the normal breathing in critical patients by damaging the lungs. The aim of this study was to evaluate the clinical outcomes of Substance P receptor Neurokinin 1 antagonist in Covid-19 patients against the usual treatments as controls.Methods It is a randomized clinical trial, open label, having two arms, one receiving normal management and care while other receiving Neurokinin-1 Receptor antagonist, Aprepitant, in addition. Dexamethasone, a corticosteroid is also administered orally to both the groups. PCR positive, hospitalized patients with more than 18 years of age, both genders, moderate to critical phase were included. 41 patients were randomly allocated in both arms, having 21 patients in group A and 20 patients in group B. Lab investigations were performed in both the groups before and after the intervention.Results Mean age of patients in group A was 50 ±18 years while 55±11 years in group B. There were 14/21 males in group A and 15/20 in group B. There were 3 critical patients in group A and 5 in group B. Biochemical and hematological parameters in both groups didn’t show much difference except the C-reactive protein reduction in the intervention group, indicative of a reduced inflammation.Conclusions The findings of this current study give a strong clue for the therapeutic potential of Aprepitant. Patients who received a combination therapy of Aprepitant and Dexamethasone showed improved clinical outcomes, laboratory findings and reduced C-reactive protein which is an inflammatory marker.Trial Registration This trial is registered in clinicaltrials.gov (NCT04468646). To Determine the Efficacy of Neurokinin 1 Receptor Antagonist as a Therapeutic Tool Against Cytokine Storm and Respiratory Failure in Covid-19 PatientsCompeting Interest StatementThe authors have declared no competing interest.Clinical TrialNCT04468646Clinical Protocols https://clinicaltrials.gov/ct2/show/NCT04468646?term=riffat+mehboob&draw=2&rank=2 Funding StatementNo funding was receivedAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:IRB approval was obtained from Bahria International Hospital where the study was performedAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData will be made available on request